**Specifications Table**TableSubject areaBiologyMore specific subject areaCervical cancer tumorigenesisType of dataFigures, TableHow data was acquiredWestern blot analysis using the Bio-Rad mini-gel apparatus; cell cycle determination using a flow cytometer (Bechman Coulter, Cytomics^TM^ FC500)Data formatFiltered and analyzedExperimental factorsCells are serum-starved for 24 h, followed by stimulation with 10% of bovine fetal serum (FBS) to examine AKT and ERK activationExperimental featuresCell cycle progression and protein expressionData source locationHamilton, Ontario, CanadaData accessibilityData is within this article

**Value of the data**•CYB5D2׳s effects on HeLa cell cycle distribution could be considered when investigating a role of CYB5D2 in regulating cell proliferation in other cell types.•The data on CYB5D2 in affecting ERK and AKT activation should be helpful in researching CYB5D2׳s role in regulating growth factor receptor signaling.•The data is useful for future investigations of CYB5D2-mediated cellular processes.

1. Data {#s0005}
=======

[Fig. 1](#f0005){ref-type="fig"} examines the cell cycle distribution of HeLa cells stably expressing either an empty vector (HeLa EV) or CYB5D2 (HeLa CYB5D2).

[Fig. 2](#f0010){ref-type="fig"} shows the status of AKT and ERK1/2 activation in HeLa EV and HeLa CYB5D2 cells. Activation of AKT and ERK1/2 was indirectly determined according to the specific phosphorylation events (see [Fig. 2](#f0010){ref-type="fig"} legend for details).

CYB5D2 can be a secretory protein [@bib2], [@bib3] that has been indicated to inhibit Neuro2a cell proliferation [@bib2]. The cell cycle distribution of HeLa cells was determined in the presence of either GST or GST-CYB5D2 ([Fig. 3](#f0015){ref-type="fig"}).

[Fig. 4](#f0020){ref-type="fig"} shows recognition of the CYB5D2 protein in human kidney tissues by the anti-CYB5D2 antibody in the presence of GST or GST-CYB5D2 as a competitor.

[Table 1](#t0005){ref-type="table"} shows the tissues used to examine the CYB5D2 protein levels in normal cervical and cervical cancer tissues.

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Experimental design and subjects {#s0015}
-------------------------------------

A tissue microarray slide was selected from US Biomax that contained 40 cervical squamous cell carcinoma and 20 normal cervical tissues ([Table 1](#t0005){ref-type="table"}). HeLa cells stably expressing EV or CYB5D2 were recently constructed [@bib1], [@bib4].

2.2. Cell cycle distribution determination {#s0020}
------------------------------------------

Cell cycle distribution was determined by individualizing cells using 0.02% EDTA in PBS. Cells were stained with a propidium iodide (PI) solution (10 mM Tris pH7.5, 150 mM NaCl, 0.05 mg/ml PI, 0.1% sodium citrate, 0.2% Triton X-100, and 0.2 mg/ml DNase-free RNase A) overnight at 4 °C in dark.Cell cycle distribution was analyzed using a fluorescent automated cell sorting (FACS) (Bechman Coulter, Cytomics^TM^ FC500).

Appendix A. Supplementary material {#s0030}
==================================
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![Examination of the effects of CYB5D2 overexpression on HeLa cell cycle distribution. HeLa EV and HeLa CYB5D2 cells were seeded in 60 mm plates, and cultured for 2 days. At density of approximately 80% confluency, cell cycle distributions were determined using a flow cytometer.](gr1){#f0005}

![The impacts of ectopic expression of CYB5D2 on serum-induced activation of AKT and ERK kinases. HeLa EV and HeLa CYB5D2 cells at approximately 90% confluency were serum starved for 24 h, and stimulated with 10% of fetal bovine serum for the indicated periods, followed by western blot analysis for the phosphorylation of AKT at serine 473 (pAKT) and ERK at threonine 183 and tyrosine 185 (pERK1/2) as well as CYB5D2 and GAPDH. Experiments were performed twice; typical results from a single repeat are shown. SF: serum free.](gr2){#f0010}

![Determination of the effects of recombinant CYB5D2 on HeLa cell cycle distribution. GST and GST-CYB5D2 recombinant proteins were purified from *E. coli*. HeLa EV and HeLa CYB5D2 cells were incubated with GST and GST-CYB5D2 at 1 mg/ml for 24 h, followed by the determination of cell cycle distribution. Cell proliferation in the presence of either protein was clearly observed. Experiments were carried out twice; typical results from a single repeat are shown.](gr3){#f0015}

![Anti-CYB5D2 antibody specifically recognizes CYB5D2. Normal human kidney tissue was immunohistochemistry (IHC) stained with anti-CYB5D2 antibody without and with addition of recombinant GST-CYB5D2 or GST. The indicated regions were enlarged 3 fold and presented underneath of the individual panels. Recombinant GST-CYB5D2 and GST were produced in *E. coli* BL21. The recombinant protein GST-CYB5D2 was generated by N-terminal fusion of the transmembrane domain deletion mutant of CYB5D2 to GST. Anti-CYB5D2 antibody was affinity-purified by using GST-CYB5D2 as previously described [@bib4]. For the competition experiments, GST-CYB5D2 or GST at 1 mg/ml was pre-incubated for one hour on ice with anti-CYB5D2 antibody (1:250) before applying to human kidney tissues.](gr4){#f0020}

###### 

Patient׳s clinical information.

Table 1.

  Patients   Pathological diagnosis                                                     Age   Grade
  ---------- -------------------------------------------------------------------------- ----- -------
  1          Endocervical type adenocarcinoma                                           42    1
  2          Endocervical type adenocarcinoma                                           42    1
  3          Endometrioid adenocarcinoma with squamous metaplasia                       48    1
  4          Endometrioid adenocarcinoma with squamous metaplasia                       48    1
  5          Endocervical type adenocarcinoma                                           52    1--2
  6          Endocervical type adenocarcinoma                                           52    1--2
  7          Endometrioid adenocarcinoma                                                32    1--2
  8          Endometrioid adenocarcinoma                                                32    1--2
  9          Instestinal type adenocarcinoma                                            72    2
  10         Instestinal type adenocarcinoma                                            72    2
  11         Endocervical type adenocarcinoma                                           43    2
  12         Endocervical type adenocarcinoma                                           43    2
  13         Clear cell adenocarcinoma                                                  40    --
  14         Clear cell adenocarcinoma                                                  40    --
  15         Instestinal type adenocarcinoma                                            51    2
  16         Instestinal type adenocarcinoma                                            51    2--3
  17         Endocervical type adenocarcinoma                                           50    2--3
  18         Endocervical type adenocarcinoma                                           50    2--3
  19         Instestinal type adenocarcinoma                                            34    2
  20         Instestinal type adenocarcinoma                                            34    2
  21         Adenocarcinoma                                                             44    3
  22         Adenocarcinoma                                                             44    3
  23         Adenocarcinoma                                                             52    3
  24         Adenocarcinoma                                                             52    3
  25         Adenocarcinoma                                                             59    3
  26         Adenocarcinoma                                                             59    3
  27         Endometrioid adenocarcinoma                                                26    3
  28         Endometrioid adenocarcinoma                                                26    3
  29         Adenocarcinoma (fibrous tissue and blood vessel)                           32    --
  30         Adenocarcinoma (fibrous tissue and blood vessel)                           32    --
  31         Adenosquamous carcinoma                                                    43    --
  32         Adenosquamous carcinoma                                                    43    --
  33         Adenosquamous carcinoma                                                    64    --
  34         Adenosquamous carcinoma                                                    64    --
  35         Adenosquamous carcinoma                                                    38    --
  36         Adenosquamous carcinoma                                                    38    --
  37         Adenosquamous carcinoma                                                    54    --
  38         Adenosquamous carcinoma                                                    54    --
  39         Adenosquamous carcinoma                                                    43    --
  40         Adenosquamous carcinoma                                                    43    --
  41         Squamous cell carcinoma                                                    53    2
  42         Squamous cell carcinoma                                                    53    2
  43         Squamous cell carcinoma                                                    27    2
  44         Squamous cell carcinoma                                                    27    2
  45         Squamous cell carcinoma                                                    68    2--3
  46         Squamous cell carcinoma                                                    68    2--3
  47         Squamous cell carcinoma                                                    37    3
  48         Squamous cell carcinoma                                                    37    3
  49         Squamous cell carcinoma                                                    43    3
  50         Squamous cell carcinoma                                                    43    3
  51         Squamous cell carcinoma                                                    69    2
  52         Squamous cell carcinoma with necrosis                                      69    2
  53         Squamous cell carcinoma (sparse)                                           48    2
  54         Squamous cell carcinoma                                                    48    2
  55         Squamous cell carcinoma                                                    36    3
  56         Squamous cell carcinoma                                                    36    3
  57         Squamous cell carcinoma                                                    63    2
  58         Squamous cell carcinoma                                                    63    2
  59         Squamous cell carcinoma                                                    47    2
  60         Squamous cell carcinoma                                                    47    1--2
  61         Squamous cell carcinoma                                                    40    2
  62         Squamous cell carcinoma                                                    40    2
  63         Squamous cell carcinoma                                                    76    2
  64         Squamous cell carcinoma                                                    76    2
  65         Squamous cell carcinoma                                                    38    3
  66         Squamous cell carcinoma (fibrous tissue and blood vessel)                  38    --
  67         Squamous cell carcinoma                                                    36    2--3
  68         Squamous cell carcinoma                                                    36    2--3
  69         Squamous cell carcinoma                                                    62    3
  70         Squamous cell carcinoma                                                    62    3
  71         Squamous cell carcinoma                                                    51    3
  72         Squamous cell carcinoma                                                    51    3
  73         Squamous cell carcinoma                                                    32    3
  74         Squamous cell carcinoma                                                    32    3
  75         Squamous cell carcinoma                                                    58    3
  76         Squamous cell carcinoma                                                    58    3
  77         Squamous cell carcinoma                                                    27    3
  78         Squamous cell carcinoma                                                    27    3
  79         Squamous cell carcinoma                                                    39    2
  80         Squamous cell carcinoma                                                    39    3
  81         Cancer adjacent normal cervical tissue                                     45    --
  82         Cancer adjacent normal cervical tissue                                     45    --
  83         Cancer adjacent normal cervical canals tissue                              62    --
  84         Cancer adjacent normal cervical canals tissue                              62    --
  85         Cancer adjacent normal cervical canals tissue                              50    --
  86         Cancer adjacent normal cervical canals tissue                              50    --
  87         Cancer adjacent normal cervical tissue of No 13                            40    --
  88         Cancer adjacent normal cervical tissue of No 13                            40    --
  89         Cancer adjacent normal cervical tissue (fibrous tissue and blood vessel)   60    --
  90         Cancer adjacent normal cervical tissue                                     60    --
  91         Normal cervical tissue                                                     18    --
  92         Normal cervical tissue                                                     18    --
  93         Normal cervical tissue                                                     15    --
  94         Normal cervical tissue                                                     15    --
  95         Normal cervical tissue (fibrous tissue and blood vessel)                   21    --
  96         Normal cervical tissue (fibrous tissue and blood vessel)                   21    --
  97         Normal cervical tissue (with hyperplasia of glandular epithelium)          21    --
  98         Normal cervical tissue (with hyperplasia of glandular epithelium)          21    --
  99         Normal cervical tissue (fibrous tissue and blood vessel)                   19    --
  100        Normal cervical tissue (fibrous tissue and blood vessel)                   19    --
